DelveInsight’s, “Type 1 Diabetes Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Type 1 Diabetes Research. Learn more about our innovative pipeline today! @ Type 1 Diabetes Pipeline Outlook
Key Takeaways from the Type 1 Diabetes Pipeline Report
- In October 2024:- Vertex Pharmaceuticals Incorporated- A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus. The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
- In October 2024:- Seraxis- This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose. Although this study is open to patients with all HLA or blood types, immunosuppression to prevent rejection will be required in this first in human study.
- In October 2024:- CellTrans Inc.- This study is a Phase 3 single center, uncontrolled trial in which 1-3 allogeneic pancreatic islet transplants are performed for each study subject. Follow-up evaluations after transplant continue for 52 weeks after the final islet transplantation. Thereafter, subjects may enroll for a 5-year follow-up study and an additional 5 year to 10 year follow-up study to evaluate the function of the islets and to measure and regulate immunosuppressive drug levels and side effects.
- DelveInsight’s Type 1 Diabetes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.
- The leading Type 1 Diabetes Companies such as Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and others.
- Promising Type 1 Diabetes Pipeline Therapies such as Euglycemic clamp with BC Combo THDB0207, ORMD-0801 Treatment A, Dapagliflozin, Mylan’s insulin glargine, Lantus®, and others.
Stay informed about the cutting-edge advancements in Type 1 Diabetes Treatments. Download for updates and be a part of the revolution in cancer care @ Type 1 Diabetes Clinical Trials Assessment
Type 1 Diabetes Emerging Drugs Profile
- Teplizumab: Prevention Bio
Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. In the pivotal TN-10 Study, a single 14-day course of teplizumab delayed insulin-dependent, clinical-stage disease by a median of at least two years in presymptomatic patients with Stage 2 T1D compared to placebo. The observed adverse events were mechanism-based, transient, and predictable, including lymphopenia, transaminase elevations, rash, and cytokine release events.
- Emricasan: Histogen
Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.
- VX-880: Vertex Pharmaceuticals
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection.
Learn more about Type 1 Diabetes Drugs opportunities in our groundbreaking Type 1 Diabetes Research and development projects @ Type 1 Diabetes Unmet Needs
Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Intravenous
- Subcutaneous
Type 1 Diabetes Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Discover the latest advancements in Type 1 Diabetes Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Type 1 Diabetes Market Drivers and Barriers, and Future Perspectives
Scope of the Type 1 Diabetes Pipeline Report
- Coverage- Global
- Type 1 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Type 1 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Type 1 Diabetes Companies- Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and others.
- Type 1 Diabetes Pipeline Therapies- Euglycemic clamp with BC Combo THDB0207, ORMD-0801 Treatment A, Dapagliflozin, Mylan’s insulin glargine, Lantus®, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Type 1 Diabetes Pipeline on our website @ Type 1 Diabetes Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Type 1 Diabetes: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Type 1 Diabetes– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Teplizumab: Provention Bio
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TTP 399: Novo Nordisk
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- SBP 101: Takeda Oncology
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Eflornithine oral: Panbela Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Type 1 Diabetes Key Companies
- Type 1 Diabetes Key Products
- Type 1 Diabetes- Unmet Needs
- Type 1 Diabetes- Market Drivers and Barriers
- Type 1 Diabetes- Future Perspectives and Conclusion
- Type 1 Diabetes Analyst Views
- Type 1 Diabetes Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/